穆龙龙;朱立;

• 1:中国医学科学院北京协和医学院北京协和医院核医学科

摘要(Abstract)：

<正>格雷夫斯病(Graves disease,GD),又称毒性弥漫性甲状腺肿,1835年由爱尔兰人Robert J.Graves最早详细描述而得名。GD是1种自身免疫性疾病,它在所有甲状腺毒性疾病中最常见,占60%～90%,在成年人的发病率约为5%,女性发病率高于男性[1]。GD的确切发病机制目前尚未完全阐明,但现有研究结果倾向于认为GD是1种由易感基因和环境

关键词(KeyWords)： Graves病;易感基因;细胞毒性T淋巴细胞相关因子4;单核苷酸多态性;促甲状腺激素受体

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 穆龙龙;朱立;

参考文献(References)：

• [1]Vanderpump MPJ,Tunbridge WMG,French JM.The incidence of thyroid disorders in the community:a twenty-year follow-up of the Wickham survey[J].Clin Endocrinol,1995,43:55-68.
• [2]Hsiao JY,Hsieh MC,Tien KJ,et al.Exon33T/T genotype of the thyroglobulin gene is a susceptibility gene for Graves'disease in Taiwanese and exon12C/C genotype protects against it[J].Clin Exp Med,2008,8:17-21.
• [3]Eschler DC,Hasham A,Tomer Y.Cutting edge:the etiology of autoimmune thyroid diseases[J].Clin Rev Allergy Immunol,2011,41:190-197.
• [4]Jozélio Freire de Carvalho,Rosa Maria Rodrigues Pereira,Yehuda Shoenfeld.Pearls in autoimmunity[J].Autoimmun Highlights,2011,2:1-4.
• [5]Zanelli E,Breedveld FC,de Vries RR.HLA association with autoimmune disease:a failure to protect?[J].Rheumatology(Oxford),2000,39:1060-1066.
• [6]Kong YC,Brown NK,Flynn JC,et al.Efficacy of HLADRB1*03:01 and H2E transgenic mouse strains to correlate pathogenic thyroglobulin epitopes for autoimmune thyroiditis[J].J Autoimmun,2011,37:63-70.
• [7]Ban Y,Davies TF,Greenberg DA,et al.Arginine at position74 of the HLA-DRb1 chain is associated with Graves'disease[J].Genes Immun,2004,5:203-208.
• [8]Yang J,Qin Q,Yan N,et al.CD40C/T(-1) and CTLA-4A/G(49)SNPs are associated with autoimmune thyroid diseases in the Chinese population[J/OL].Endocrine,(2011-08-25)[2011-09-26]http://www.springer.com/?SGWID=0-102-24-0-0&searchType=EASY_CDA&query Text=CD40+C2FT28-129+and+CTLA-4+A2FG284929+SNPs+are+associated+with+autoimmune+thyroid+diseases+in+the+Chinese+population.
• [9]Resetkova E,Kawai K,Enomoto T,et al.Antibody to gp39,the ligand for CD40 significantly inhibits the humoral response from Graves'thyroid tissues xenografted into severe combined immuno deficient(SCID)mice[J].Thyroid,1996,6:267-273.
• [10]Chen CR,Aliesky HA,Guo J,et al.Blockade of co-stimulation between T cells and antigen-presenting cells:an approach to suppress murine Graves'disease induced using thyrotropin receptor-expressing adenovirus[J].Thyroid,2006,16:427-434.
• [11]Jacobson EM,Concepcion E,Oashi T,et al.A Graves'disease-associated Kozak sequence single-nucleotide polymorphism enhances the efficiency of CD40 gene translation:a case for translational pathophysiology[J].Endocrinology,2005,146:2684-2691.
• [12]Anjos S,Nguyen A,Ounissi-Benkalha H,et al.A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen4results in inefficient glycosylation of the susceptibility allele[J].J Biol Chem,2002,277:46478-46486.
• [13]Ban Y,Davies TF,Greenberg DA,et al.Analysis of the CTLA-4,CD28,and inducible costimulator(ICOS)genes in autoimmune thyroid disease[J].Genes Immun,2003,4:586-593.
• [14]Takara M,Kouki T,DeGroot LJ.CTLA-4 AT-repeat polymorphism reduces the inhibitory function of CTLA-4 in Graves'disease[J].Thyroid,2003,13:1083-1089.
• [15]Finn PW,He H,Wang Y,et al.Synergistic induction of CTLA-4 expression by costimulation with TCR plus CD28signals mediated by increased transcription and messenger ribonucleic acid stability[J].J Immunol,1997,158:40744081.
• [16]Chu X,Pan CM,Zhao SX,et al.A genome-wide association study identifies two new risk loci for Graves'disease[J].Nat Genet,2011,43:897-901.
• [17]Gu LQ,Zhu W,Zhao SX,et al.Clinical associations of the genetic variants of CTLA-4,Tg,TSHR,PTPN22,PTPN12 and FCRL3 in patients with Graves'disease[J].Clin Endocrinol(Oxf),2010,72:248-255.
• [18]Collins JE,Heward JM,Carr-Smith J,et al.Association of a rare thyroglobulin gene microsatellite variant with autoimmune thyroid disease[J].J Clin Endocrinol Metab,2003,88:5039-5042.
• [19]Robinson JH,Delvig AA.Diversity in MHC class II antigen presentation[J].Immunology,2002,105:252-262.
• [20]Gebe JA,Swanson E,Kwok WW.HLA class II peptidebinding and autoimmunity[J].Tissue Antigens,2002,59:78-87.
• [21]Davies TF,Ando T,Lin RY,et al.Thyrotropin receptor-associated diseases:from adenomata to Graves disease[J].J Clin Invest,2005,115:1972-1983.
• [22]Tonacchera M,Pinchera A.Thyrotropin receptor polymorphisms and thyroid diseases[J].J Clin Endocrinol Metab,2000,85:2637-2639.
• [23]Brand OJ,Gough SC.Genetics of thyroid autoimmunity and the role of the TSHR[J].Mol Cell Endocrinol,2010,322:135-143.
• [24]D'Silva KJ,Zamora MB,Gerlach J,et al.Increased representation of the PTPN22 mutation in patients with immune thrombocytopenia[J].J Thromb Haemost,2010,8:20762078.
• [25]Dechairo BM,Zabaneh D,Collins J,et al.Association of the TSHR gene with Graves'disease:the first disease specific locus[J].Eur J Hum Genet,2005,13:1223-1230.
• [26]Bottini N,Vang T,Cucca F,et al.Role of PTPN22 in type1diabetes and other autoimmune diseases[J].Semin Immunol,2006,18:207-213.
• [27]Ban Y,Tozaki T,Taniyama M,et al.The codon 620 single nucleotide polymorphism of the protein tyrosine phosphatase22gene does not contribute to autoimmune thyroid disease susceptibility in the Japanese[J].Thyroid,2005,15:1115-1118.
• [28]Brix TH,Kyvik KO,Christensen K,et al.Evidence for a major role of heredity in Graves'disease:a population-based study of two Danish twin cohorts[J].J Clin Endocrinol Metab,2001,86:930-934.
• [29]Tomer Y,Huber A.The etiology of autoimmune thyroid disease:a story of genes and environment[J].J Autoimmun,2009,32:231-239.